Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
VolitionRx Limited (NYSE American: VNRX), a biotechnology company specializing in in vitro and in vivo diagnostic substances, announced today the filing of a new registration statement with the Securities and Exchange Commission (SEC). The company, currently trading at $0.54 per share, has shown strong revenue growth of 59.1% over the last twelve months, though InvestingPro data indicates challenges with its current ratio of 0.52. This filing pertains to the registration of an aggregate of 35,867,306 shares of common stock, which are issuable upon the exercise of previously issued warrants. According to InvestingPro analysis, the company faces some financial challenges, with EBITDA at -$25.91M and short-term obligations exceeding liquid assets. Subscribers to InvestingPro can access 7 additional key insights and a comprehensive Pro Research Report for deeper analysis.
The company, headquartered in Henderson, Nevada, initially registered these Warrant Shares under a Shelf Registration Statement on Form S-3 filed on September 24, 2021, and subsequently declared effective by the SEC on November 8, 2021. VolitionRx is now transferring the registration of these shares to a new Registration Statement on Form S-1.
The action taken by VolitionRx indicates a strategic move to manage its share registration more effectively. The company has clarified that no new shares are being registered; only those previously accounted for under the Shelf Registration Statement are being transitioned. Once the New Registration Statement is declared effective by the SEC, VolitionRx plans to withdraw the Warrant Shares from the Shelf Registration Statement in accordance with Rule 477 of the Securities Act.
This administrative update does not involve the filing of any new shares and is solely a re-registration of shares previously filed. The company has not disclosed any additional financial terms or specific plans regarding the Warrant Shares at this time.
VolitionRx’s announcement is a matter of regulatory compliance and does not reflect any immediate change in the company’s operations or financial position. The information reported in this article is based on a press release statement and has not been independently verified.
Investors and stakeholders in VolitionRx can follow the company’s filings and announcements for further details and updates on the effectiveness of the New Registration Statement and the subsequent withdrawal of the Warrant Shares from the Shelf Registration Statement. With the next earnings report expected on May 7, 2025, InvestingPro subscribers can access detailed financial health scores, valuation metrics, and expert analysis to make more informed investment decisions.
In other recent news, VolitionRx Limited reported a notable revenue increase for Q4 2024, with earnings reaching $1.2 million, marking a 59% rise compared to the previous year. This growth was primarily driven by the Nu.Q Vet cancer test, which saw sales of $800,000, reflecting a 75% increase from the prior year. The company also managed to reduce operating expenses by 23%, showcasing improved cost management. Despite these positive financial results, concerns remain about VolitionRx’s limited cash reserves, which stood at $3.3 million at year-end. Analysts have shown interest in the company’s future prospects, particularly regarding its plans to achieve cash neutrality in 2025 and its ongoing efforts to expand the Nu.Q platform. Discussions about potential licensing deals for human applications are underway, with VolitionRx aiming to replicate its success in the veterinary space. Additionally, the company is engaged in strategic discussions to commercialize its epigenetics portfolio and expand its clinical studies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.